3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myeloid, Acute
7
Lymphoma
5
Leukemia
5
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Squamous Cell Carcinoma of Head and Neck
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Stomach Neoplasms
2
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, B-Cell
2
Hodgkin Disease
2
Carcinoma, Non-Small-Cell Lung
2
Anemia, Refractory, with Excess of Blasts
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
fludarabine phosphate
×
Clear all
NCT05566223
2026-02-23
CheckCell-2
Intima Bioscience, Inc.
Phase 1/2
Withdrawn